Evidence map›Paper›PMID 40371988›Full record

ArticleCancer research communications2025

Targeting the Glucose-Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth.

Simbarashe Mazambani, Seong-Ho Park, Joshua H Choe, An H Nguyen, Bok-Soon Lee, Ji Yun Jeong, Shin Yup Lee, Chul-Ho Kim, Yea-In Park, Joselyn Padilla and 8 more

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Simbarashe Mazambani *Department of Biological Sciences, The University of Texas at Dallas, Richardson, Texas.ORCID 0000-0002-6554-7889
Seong-Ho Park *Department of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0009-0009-9717-371X
Joshua H Choe *Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7094-3766
An H NguyenDepartment of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0009-0005-9673-2752
Bok-Soon LeeDepartment of Otolaryngology, Ajou University School of Medicine, Suwon, Korea.ORCID 0000-0002-0896-2883
Ji Yun JeongDepartment of Pathology, Kyungpook National University School of Medicine, Daegu, Korea.ORCID 0000-0001-6167-4998
Shin Yup LeeDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.ORCID 0000-0002-2121-7335
Chul-Ho KimDepartment of Otolaryngology, Ajou University School of Medicine, Suwon, Korea.ORCID 0000-0002-2161-4488
Yea-In ParkDepartment of Biochemistry & Molecular Medicine, George Washington University School of Medicine and Health Sciences, GW Cancer Center, Washington, District of Columbia.ORCID 0000-0002-7851-8470
Joselyn PadillaDepartment of Biochemistry & Molecular Medicine, George Washington University School of Medicine and Health Sciences, GW Cancer Center, Washington, District of Columbia.ORCID 0000-0002-1898-1041
Jiyoung LeeDepartment of Biochemistry & Molecular Medicine, George Washington University School of Medicine and Health Sciences, GW Cancer Center, Washington, District of Columbia.ORCID 0000-0001-8503-4805
Dinesh ThotalaDepartment of Radiation Oncology, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0000-0001-5355-6406
Tae Gyu OhDepartment of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0000-0002-2756-3546
Pankaj K SinghDepartment of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0000-0001-8903-0131
Hoon HurDepartment of Surgery, Ajou University School of Medicine and Cancer Biology Graduate Program, Ajou University Graduate School of Medicine, Suwon, Korea.ORCID 0000-0002-5435-5363
Junho K HurDepartment of Genetics, College of Medicine, Hanyang University, Seoul, Korea.ORCID 0000-0003-3794-1149
Jung-Whan KimDepartment of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma.ORCID 0000-0002-7829-1480
Tae Hoon KimDepartment of Biological Sciences, The University of Texas at Dallas, Richardson, Texas.ORCID 0000-0003-3950-7557

Funding

Tissue Core-UNMC Rapid Autopsy ProgramU54CA274329 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Pankaj Kumar Singh · 2022 to 2026
$7.8M
Targeting Tumor-Stromal Metabolic Cross-Talk in Pancreatic CancerR01CA163649 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Pankaj Kumar Singh · 2012 to 2026
$5.4M
Mitochondrial calcium signaling in pancreatic cancer metastasis and progressionR01CA256911 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Pankaj Kumar Singh, Shengyu Yang · 2022 to 2026
$3.2M
Understanding lactate catabolism by BACH1 in triple negative breast cancerR37CA270536 · NCI · GEORGE WASHINGTON UNIVERSITY · PI Jiyoung Lee · 2022 to 2026
$2.4M
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic CancerR01CA270234 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Pankaj Kumar Singh · 2022 to 2026
$2.2M
NCI NIH HHS R01 CA163649NCI NIH HHS R01 CA256911NCI NIH HHS R01 CA270234NCI NIH HHS R37 CA270536NCI NIH HHS U54 CA274329
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)-mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer-specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo, partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. SIGNIFICANCE: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.

Indexed as

GlucoseGlucose Transporter Type 1Head and Neck NeoplasmsInsulinOxidative StressSquamous Cell Carcinoma of Head and NeckAnimalsCell Line, TumorCell ProliferationHumansMiceMice, KnockoutReactive Oxygen SpeciesSignal TransductionGlucoseGlucose Transporter Type 1InsulinReactive Oxygen SpeciesSLC2A1 protein, human

Identifiers

PMID40371988
PMCPMC12141995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.